BEAM
Beam Therapeutics Inc.
NASDAQ · USHealthcareBiotechnology
$26.33-4.36%
Price as of Jul 20, 2026
BEAM financials
Beam Therapeutics Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $139.7M | $63.5M | $377.7M | $60.9M |
| Cost of revenue | $22.3M | $367.6M | $0.00 | $311.6M |
| Gross profit | $117.4M | -$304.0M | $377.7M | -$250.7M |
| Operating expenses | $501.1M | $111.5M | $554.2M | $87.8M |
| Operating income | -$383.7M | -$415.6M | -$176.5M | -$338.5M |
| Net income | -$80.0M | -$376.7M | -$132.5M | -$289.1M |
| EBITDA | -$29.9M | -$354.8M | -$101.6M | -$271.5M |
| Basic EPS | $-0.81 | $-4.58 | $-1.72 | $-4.13 |
| Diluted EPS | $-0.81 | $-4.58 | $-1.72 | $-4.13 |
| Balance sheet | ||||
| Cash & equivalents | $294.9M | $282.0M | $435.9M | $232.8M |
| Total assets | $1.5B | $1.1B | $1.5B | $1.3B |
| Total liabilities | $242.8M | $370.3M | $478.4M | $608.2M |
| Stockholders’ equity | $1.2B | $733.5M | $981.3M | $733.5M |
| Total debt | $293.9M | $161.4M | $172.7M | $179.0M |
| Net debt | -$1.1M | -$120.5M | -$263.2M | -$53.8M |
| Cash flow | ||||
| Operating cash flow | -$345.1M | -$347.2M | -$149.2M | $22.5M |
| Capital expenditure | -$14.9M | -$8.9M | -$33.7M | -$49.0M |
| Free cash flow | -$360.0M | -$356.2M | -$182.9M | -$26.4M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |